Outcomes of HIV-infected patients treated for recurrent tuberculosis with the standard retreatment regimen

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 6, 2012, Pages 841-845

  McGreevy, Jolion ^a   Jean Juste, M A ^a   Severe, P ^a   Collins, S ^b   Koenig, S ^c   Pape, J W ^a,b   Fitzgerald, D W ^b  

^a Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Human immunodeficiency virus; Retreatment; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HAITI; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT INFECTION; RETREATMENT; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HAITI; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84861127042     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0210     Document Type: Article

References (14)

1. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2009.
2. Fitzgerald D W, Desvarieux M, Severe P, Joseph P, Johnson W D Jr, Pape J W. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356: 1470-1474.
3. World Health Organization. Improving the diagnosis and treatment of smear-negative pulmonary and extra-pulmonary tuberculosis among adults and adolescents: recommendations for HIV-prevalent and resource-constrained settings. Geneva, Switzerland: WHO, 2007.
4. Schreiber Y S, Herrera A F, Wilson D, et al. Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area. Int J Tuberc Lung Dis 2009; 13: 1274-1280.
5. Jones-López E C, Ayakaka I, Levin J, et al. Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med 2011; 8: e1000427.
6. World Health Organization. Global tuberculosis control. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO, 2010.
7. Leger P, Charles M, Severe P, et al. 5-year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med 2009; 361: 828-829.
8. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2003 revision. Geneva, Switzerland: WHO, 2004.
9. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. Geneva, Switzerland: WHO, 2006.
10. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005; 353: 2325-2331.
11. American Thoracic Society. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 1990; 142: 725-735.
12. Pape J W, Jean S S, Ho J L, Hafner A, Johnson W D Jr. Effects of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-272. (Pubitemid 23224420)
13. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369: 2042-2049. (Pubitemid 46908825)
14. Fawzi W W, Msamanga G I, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351: 23-32. (Pubitemid 38857244)